DEALS: Actavis buys generic unit for $810M


Actavis buys generic unit for $810M


DEALS

WHO

WITH

WHAT

SCOOP

Actavis Group

Alpharma

Acquisition of generic drug unit

The $810M deal narrows Alpharma's focus while boosting Actavis' presence in the US generics business.

genOway

IngenKO

Acquisition of assets

IngenKo's closing set up a deal that expands genOway's work in transgenesis, taking over a number of projects in the works.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.